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Abstract The system of matrix metalloproteinases
(MMPs) and their tissue inhibitors (TIMPs) may play a
key role in atherogenesis of chronic kidney disease (CKD)
patients by its impact on matrix accumulation. Connections
with inflammation, stress, or endothelial dysfunction are
also probable. However, the data on correlations between
these parameters in CKD patients are scarce in adults and
absent in children. The aim of our study was to evaluate
serum concentrations of MMP-2, MMP-9, TIMP-1, and
TIMP-2, as well as their correlations with markers of stress
response (Hsp90-α, anti-Hsp60), endothelial dysfunction
(sE-selectin), and inflammation (high-sensitivity C-reactive
protein) in CKD children treated conservatively. Thirty-
seven patients were divided into two groups according to
the CKD stage (gr.CKDI, 19 children with CKD stages
2–3; gr.CKDII, 18 subjects with CKD stages 4–5). Twenty-
four age-matched healthy subjects served as controls.
Serum concentrations of MMP-2, MMP-9, TIMP-1,
TIMP-2, Hsp90-α, anti-Hsp60, and sE-selectin were
assessed by ELISA. Median values of MMP-2, MMP-9,
TIMP-1, and TIMP-2 were significantly higher in all CKD
children vs. controls and were increased in patients with
CKD stages 4–5 vs. CKD stages 2–3. Hsp90-α, anti-
Hsp60, sE-selectin, and glomerular filtration rate predicted
the values of MMPs and TIMPs. Chronic kidney disease in
children is characterized by MMP/TIMP system dysfunc-
tion, aggravated by the progression of renal failure.
Correlations between examined parameters, heat shock
proteins, and markers of endothelial damage suggest the
possibility of MMP/TIMP application as indicators of stress
response and atherogenesis in children with CKD on
conservative treatment.
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Introduction
Endothelial dysfunction, inflammation, dyslipidemia, and
autoimmune reactions are key elements in the pathogenesis
of atherosclerosis (Blasi 2008; Nilsson and Hansson 2008).
Heat shock proteins (HSPs) and their antibodies also
influence the process of atherosclerosis (Wick et al. 2004;
Rigano et al. 2007). The best described example of such
impact is that of Hsp60 and anti-Hsp60 working together.
Anti-Hsp60 is generated in response to both bacterial and
human Hsp60 and triggers autoimmune reactions against
one’s own HSPs (Pockley et al. 1999; Perschinka et al.
2003; Wu and Tanguay 2006). The impact of anti-Hsp60 on
innate immunity is also projected by the activation of
macrophages and by stimulation of nuclear factor (NF)-κB,
which is one of the regulators of matrix metalloproteinase
(MMP) and tissue inhibitor of metalloproteinase (TIMP)
secretion (Schett et al. 1995). Similar activity has been
described very recently in the case of Hsp90-α (Madrigal-
Matute et al. 2010). Moreover, the role of HSPs in
predicting risk of acute coronary syndrome and progression
of atherosclerosis has also been confirmed (Dulin et al.
2010; Zhang et al. 2010).
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extracellular matrix metabolism in myocardial and
vascular remodeling as being another new component
of the atherosclerotic puzzle (Johnson et al. 2005, 2006;
Kuzuya et al. 2006). Therefore, matrix metalloprotei-
nases, endopeptidases with proteolytic activity, as well
as their tissue inhibitors, have been proposed as a group
of factors that add to the pathogenesis of atherosclero-
sis. Animal models and in vitro investigations have
shown their multifaceted actions, varying from protec-
tive and antiatherogenic in the case of TIMP-2, through
neutral of TIMP-1 or ambiguous of MMP-9, to
proatherogenic of MMP-2 (Luttun et al. 2004;d e
Nooijer et al. 2006;J o h n s o ne ta l .2005, 2006; Kuzuya
et al. 2006).
Moreover, gelatinases A and B (MMP-2 and MMP-9)
occupy an established position among risk factors for
myocardial infarction (Jefferis et al. 2010) and as predictors
of mortality due to acute coronary syndrome (Dhillon et al.
2010), whereas their tissue inhibitors TIMPs have an
impact on postmyocardial infarction remodeling (Kandalam
et al. 2010) and correlate positively with left ventricular
mass and wall thickness (Hansson et al. 2009). The role of
MMPs in kidney disease has been studied extensively
(Catania et al. 2007), and special attention has been paid to
the impact on ischemic acute renal injury and scarring in
the course of glomerulopathies (Caron et al. 2005; Cheng
et al. 2006; Johnson et al. 2002). However, the data on their
role in chronic kidney disease, characterized by accelerated
progression of atherosclerosis, are scarce and come mainly
from adult patients on hemodialysis (Preston et al. 2002;
Pawlak et al. 2007).
There are no data so far on MMPs and TIMPs in
pediatric patients with chronic kidney disease on conserva-
tive treatment. Therefore, the first aim of our study was to
evaluate the levels of MMP-2, MMP-9, TIMP-1, and
TIMP-2 in serum samples from children in different stages
of chronic kidney disease treated conservatively. The
second goal was to analyze whether there is any relation-
ship between those parameters and other factors predispos-
ing to atherosclerosis, such as disturbed stress response
(Hsp90-α, anti-Hsp60), endothelial activation (sE-selectin),
inflammation (high-sensitivity C-reactive protein (hsCRP)),
or dyslipidemia.
Subjects and methods
Sixty-one patients enrolled in the study were divided into
three groups.
The first group (chronic kidney disease (CKD) I)
consisted of 19 patients (10 girls, nine boys, median age
of 8.5 years, interquartile range of 4.5–15 years) with CKD
stages 2–3 treated conservatively (median glomerular
filtration rate (GFR) calculated according to the Schwartz
formula 51 ml/min per 1.73 m
2). The factors causing CKD
were: reflux nephropathy (seven cases), chronic glomeru-
lonephritis (five), chronic pyelonephritis (one), polycystic
kidney disease (four), hemolytic uremic syndrome (one),
and cystinosis (one).
The second group (CKD II) contained 18 patients
(10 girls, eight boys; median age of 11 years, interquartile
range of 5–17.5 years) with CKD stages 4–5 on conserva-
tive treatment (median GFR 23 ml/min per 1.73 m
2).
Primary diseases causing CKD were reflux nephropathy
(nine cases), chronic glomerulonephritis (six), lupus
nephropathy (one), neurogenic bladder (one), hemolytic
uremic syndrome (one). In all patients, phosphate binders
and vitamin D metabolites were supplemented.
Twenty-four children (13 girls, 11 boys, median age of
10.5 years, range of 5–16.5 years) with primary nocturnal
enuresis, with normal kidney function, served as controls.
None of the patients showed clinical evidence of
infection, malignancy, or vasculitis, suffered from diabetes,
smoked, and took antibiotics, corticosteroids, or immuno-
suppressive therapy. All the CKD children had blood
pressure values below the 90th percentile for smaller
children and below 120/80 mmHg for adolescents, accord-
ing to the criteria of the fourth report on high blood
pressure in children and adolescents (National 2004). CKD
stage 2–3 children, except for three subjects receiving
angiotensin-converting enzyme (ACE) inhibitors in neph-
roprotective doses, did not require antihypertensive drugs.
In the CKD stage 4–5 group blood pressure was well
controlled either without medication (13 children) or with
the use of ACE inhibitors (three patients) or ARB (one
child).
Informed consent was obtained from the subjects and
their parents, if necessary. The research project was
approved by the University ethics committee, in accordance
with the Helsinki declaration.
Blood samples were drawn from peripheral veins after
an overnight fast. Samples were clotted for 30 min and
centrifuged at 4°C for 10 min, and then serum was stored at
−20°C until assayed. Serum concentrations of MMP-2
(gelatinase A), MMP-9 (gelatinase B), TIMP-1, TIMP-2,
sE-selectin, Hsp90-α, and anti-Hsp60 were evaluated by
commercially available ELISA kits (Stressgen, R&D
Systems, UK). In the case of MMP/TIMP, standards and
serum samples were transferred to 96-well microplates
precoated with recombinant antibodies to human MMP-2,
MMP-9, TIMP-1, and TIMP-2. Each sample was tested in
duplicate, and the arithmetical mean was considered a final
result. Measurements were performed according to the
manufacturer’s instructions; results were calculated by
reference to standard curves.
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sE-selectin were described in our previous publication
(Musiał et al. 2010).
In all patients, the kidney function was assessed,
calculated by the Schwartz formula. The lipid profile (total
cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, triglycerides by
BioSystems, Barcelona, Spain) and hsCRP as a marker of
inflammation (nephelometry by Dade Behring, Marburg,
Germany) were also evaluated.
Statistical analysis
Results are expressed as median values and interquartile
ranges. Differences between all groups were evaluated using
nonparametric tests (Kruskal–Wallis, Mann–Whitney U).
The relations between parameters were assessed by linear
regression analysis. The linear regression equations were
calculated as y ¼ b  þ a (y, dependent variable; β, regres-
sion coefficient; x, independent variable; a, constant term).
We presented only those equations where both regression
coefficient and constant term were statistically significant.
Statistical analysis was performed using the package Statis-
tica ver. 8.0. A p value of <0.05 was considered significant.
Results
MMP-2 and MMP-9
MMP-2 and MMP-9 concentrations in all CKD children
were significantly higher vs. controls (p<0.000001), and
the levels in the CKD stage 4–5 subgroup were increased
when compared to CKD stages 2–3 (Fig. 1a, b).
TIMP-1 and TIMP-2
In the case of TIMP-1, the concentrations in the CKD
group were also elevated vs. controls (p<0.001). However,
the median TIMP-1 values in the CKD stages 2–3 were
comparable, whereas in the CKD stages 4–5 they were
higher than in the control group (Fig. 1c). TIMP-2 levels
were increased in CKD children vs. controls (p<0.000001)
and rose with the progression of renal failure (Fig. 1d).
MMP/TIMP ratios
When MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios were
assessed, the first was significantly higher (p<0.000001)
and the second was significantly lower (p<0.000001) in all
CKD children than in the control group. However, none of
them could differentiate between the CKD stage 2–3 and
the CKD stage 4–5 groups (Fig. 1e, f).
Hsp90-α, anti-Hsp60, sE-selectin
Hsp90-α, anti-Hsp60, and sE-selectin serum concentrations
in the CKD population were significantly higher than in the
control group (Table 1).
hsCRP, lipid profile
High-sensitivity CRP and total cholesterol levels did not
show significant differences between CKD children and
controls (Table 1). HDL concentrations were increased,
whereas those of LDL and triglycerides were decreased in
CKD patients versus controls (Table 1).
Linear regression analysis
In all CKD children, MMPs and TIMPs correlated with
each other. We have also found correlations between
MMPs, TIMPs, and other examined parameters. In detail,
Hsp90-α, anti-Hsp60, sE-selectin, and GFR predicted the
values of MMP-2, MMP-9, and TIMP-1 (Table 2). In the
case of TIMP-1, such prediction concerned sE-selectin and
GFR (Table 2).
No associations between MMP/TIMP, the lipid profile,
and hsCRP were observed.
Discussion
In our study, we have shown for the first time the
dysfunctional MMP/TIMP system and its correlation to
markers of stress response in children with chronic kidney
disease treated conservatively.
Serum MMP-2 concentrations in the examined popula-
tion were elevated, when compared to controls, similar to
the results obtained in adults by others (Peiskerova et al.
2009; Chang et al. 2006). The novelty of our observation
was the fact that MMP-2 levels increased gradually with the
progression of CKD and correlated with GFR. Although
Chang et al. (2006) have previously reported the correlation
between gelatinases and serum creatinine, the interpretation
of these results should be viewed with caution due to
methodological inconsistencies (e.g., plasma collection in
ethylenediaminetetraacetic acid (EDTA)-containing tubes,
although the use of EDTA is not recommended by the
manufacturer due to its chelating properties). We have also
revealed the correlations between MMP-2, stress response,
and endothelial activation in the pediatric CKD population.
These findings add new data to the knowledge of
cardiovascular complication pathogenesis in CKD children
(Mitsnefes 2005). Since MMP-2 has recently been defined
as a predictor of mortality in acute coronary syndrome
(Dhillon et al. 2010) and its correlation with arterial
Matrix metalloproteinases and stress response in CKD children 99stiffness in CKD patients has been revealed (Chung et al.
2009), the usefulness of gelatinase A as one of the potential
markers of atherogenesis in children with CKD seems
justified.
The data on MMP-9 concentrations in CKD patients are
scarce and contradictory and concern only adults. Chang
et al. (2006) found decreased levels of gelatinase B,
whereas Peiskerova et al. (2009) noticed no difference
between controls and CKD patients. In our group, a gradual
increase was observed, together with an inverse correlation
to GFR values. Such discrepancies may result from
methodology or differences in the profile of examined
 median
 25%-75%
 min - max
 median
 25%-75%
 min - max
 median
 25%-75%
 min - max
 median
 25%-75%
 min - max
 median
 25%-75%
 min - max
 median
 25%-75%
 min - max
Control gr CKDI CKDII
Examined groups
Control gr CKDI CKDII
Examined groups
Control gr CKDI CKDII
Examined groups
Control gr CKDI CKDII
Examined groups
Control gr CKDI CKDII
Examined groups
Control gr CKDI CKDII
Examined groups
80
10
120
140
160
180
200
S
e
r
u
m
 
M
M
P
-
2
 
[
n
g
/
m
l
]
p < 0.000001 
CKDI vs. control gr 
CKDII vs. control gr
p < 0.000001 
CKDII vs. CKDI
50
100
150
200
250
300
350
400
450
500
550
S
e
r
u
m
 
M
M
P
-
9
 
[
n
g
/
m
l
]
p < 0.000001 
CKDI vs. control gr 
CKDII vs. control gr
p < 0.000001 
CKDII vs. CKDI
20
40
60
80
100
120
140
160
S
e
r
u
m
 
T
I
M
P
-
1
 
[
n
g
/
m
l
]
p < 0.000001 
CKDII vs. control gr
p < 0.00001 
CKDII vs. CKDI
p = 0.78 
CKDI vs. control gr
20
40
60
80
100
120
140
160
180
S
e
r
u
m
 
T
I
M
P
-
2
 
[
n
g
/
m
l
]
p < 0.000001 
CKDI vs. control gr 
CKDII vs. control gr
p < 0.001 
CKDII vs. CKDI
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
4,5
M
M
P
-
9
/
T
I
M
P
-
1
r
a
t
i
o
 p < 0.00001 
CKDI vs. control gr 
CKDII vs. control gr
p = 0.96 
CKDII vs. CKDI
0,8
1,0
1,2
1,4
1,6
1,8
2,0
2,2
2,4
2,6
2,8
3,0
3,2
3,4
M
M
P
-
2
/
T
I
M
P
-
2
 
r
a
t
i
o
p < 0.00001
CKDI vs. control gr 
CKDII vs. control gr
p = 0.06 
CKDII vs. CKDI
ab
cd
ef
Fig. 1 Serum concentrations of examined parameters (a MMP-2; b MMP-9; c TIMP-1; d TIMP-2; e MMP-9/TIMP-1; f MMP-2/TIMP-2) in the
CKD children and in the control group
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et al. (2006) contained adults with mean creatinine
clearance (CCr) of 11 ml/min and was divided into
subgroups with CCr less than 10 ml/min, between 10 and
15 ml/min, and over 15 ml/min. Our patients had relatively
higher GFR values (CKD 2–3 51 ml/min; CKD 4–5 23 ml/
min), and we had no subjects with CCr less than 15 ml/min.
Another reason for difficulties in the interpretation of
MMP-9 elevation may be the fact of its ambiguous activity
in in vitro investigations. Gelatinase B was described as
protecting plaque stability in its early stage and increasing
its vulnerability in the case of advanced lesion (Luttun et al.
2004; de Nooijer et al. 2006).
Moreover, matrix metalloproteinases are subject to
different factors modifying their activity. The levels of
MMPs depend on the presence of diabetic nephropathy
(Rysz et al. 2007), hypercholesterolemia (El Messal et al.
2006), inflammation (Addabbo et al. 2007), increased
oxidative stress (Valentin et al. 2005; Castro et al. 2009),
ACE inhibitors (Lods et al. 2003), and hypertension (Castro
et al. 2008). Although we did not observe the correlation of
examined enzymes with classical indicators of atheroscle-
rotic changes, such as lipids or hsCRP, we have added sE-
selectin, a marker of endothelial dysfunction, and heat
shock proteins, to that list. Moreover, serum Hsp90-α, anti-
Hsp60, sE-selectin, and GFR predicted the concentrations
of MMPs and TIMPs in all CKD children. Therefore, it is
probable that in the pediatric CKD population metal-
loproteinases share common features with stress markers
rather than with those typical for atherosclerosis. The
enzyme levels, increasing progressively with aggravation
of kidney failure, stress conditions, and toxemia, would
seem to confirm such a theory. However, correlations of
MMPs and TIMPS with Hsp90-α and anti-Hsp60 in CKD
patients are new findings, not confirmed by any earlier
study. The possible explanation for such links might lie in
the common points of signaling pathway regulation. Both
Hsp90-α and Hsp60 increase secretion of cytokines (e.g.,
Table 2 The statistically significant correlations between the examined parameters assessed by linear regression analysis in the CKD patients
Dependent variable Independent variable Regression coefficient β Constant term 95% confidence interval (CI) p
CKD patients
MMP-2 (ng/ml) Hsp90-α (ng/ml) −1.18 196.28 169.09–176.22 0.00
MMP-2 (ng/ml) Anti-Hsp60 (ng/ml) −0.13 179.31 168.96–177.96 0.02
MMP-2 (ng/ml) sE-selectin (pg/ml) 0.70 123.93 168.60–174.59 0.00
MMP-2 (ng/ml) GFR (ml/min) −0.49 186.93 166.64–177.58 0.00
MMP-9 (ng/ml) Hsp90-α (ng/ml) −8.82 513.79 311.73–362.88 0.00
MMP-9 (ng/ml) Anti-Hsp60 (ng/ml) −0.85 381.53 308.97–375.92 0.03
MMP-9 (ng/ml) sE-selectin (pg/ml) 4.60 17.42 305.03–355.08 0.00
MMP-9 (ng/ml) GFR (ml/min) −3.99 460.64 301.59–379.89 0.00
TIMP-1 (ng/ml) Hsp90-α [ng/ml] −2.20 147.27 95.09–111.35 0.00
TIMP-1 (ng/ml) Anti-Hsp60 (ng/ml) −0.29 118.59 95.79–114.40 0.01
TIMP-1 (ng/ml) sE-selectin (pg/ml) 1.53 −2.89 95.09–106.95 0.00
TIMP-1 (ng/ml) GFR (ml/min) −1.17 137.92 91.98–113.91 0.00
TIMP-2 (ng/ml) sE-selectin [pg/ml] 0.54 75.71 106.22–118.67 0.01
TIMP-2 (ng/ml) GFR (ml/min) −0.58 128.80 91.98–113.91 0.03
Parameter Median values (lower–upper quartile) of analyzed parameters
Control group CKD patients
n=24 n=37
Hsp90-α (ng/ml) 5.0 (4.5–5.5) 20.0 (15.0–25.0)****
Anti-Hsp60 (ng/ml) 11.3 (8.2–26.7) 46.0 (14.9–81.7)*
sE-selectin (ng/ml) 26.1 (22.2–28.0) 68.0 (54.0–80.0)****
hsCRP (mg/l) 0.33 (0.21–0.63) 0.28 (0.16–0.81) NS
CHOL (mg/dl) 188.0 (181.0–196.0) 193.0 (167.8–235.3) NS
HDL (mg/dl) 62.0 (59.0–67.0) 52.0 (49.5–61.0)**
LDL (mg/dl) 99.5 (91.0–109.0) 100.0 (95.0–147.0)**
TGL (mg/dl) 86.0 (66.5–100.0) 115.0 (100.0–159.0)***
Table 1 The median values and
interquartile ranges of examined
parameters in the patients with
CKD and in the control group
NS nonsignificant
*p<0.01; **p<0.001; ***p<
0.0001; ****p<0.00001 CKD
vs. controls
Matrix metalloproteinases and stress response in CKD children 101TNF-α) and adhesion molecules (e.g., sE-selectin) and
trigger NF-κB activity, which then upregulate the synthesis
of MMPs and TIMPs (Zhang et al. 1998; Kol et al. 1999;
Businaro et al. 2009; Madrigal-Matute et al. 2010).
Therefore, there is a functional chain suggesting the reason
for the observed correlations. Such connection has not been
proven in the case of TIMP-2, thus explaining the lack of
relation between Hsp90-α and anti-Hsp60 and TIMP-2 in
our population. The question whether any direct regulation
between HSP and MMP/TIMP system takes place,
although intriguing, requires further detailed investigation.
We have also revealed that all examined MMPs and
TIMPs correlate with each other, thus aggravating the
complexity of interrelations between them and forming a
kind of functional network including processes engaged in
reactions to stress conditions.
TIMP-1 concentrations remained unchanged in children
with CKD stages 2–3 and increased with disease progres-
sion, being higher in CKD stages 4–5 than in controls and
in CKD stages 2–3. As far as we are concerned, there are
no available data on other studies evaluating TIMP-1 in
various CKD stages. One of the possible explanations is
that TIMP-1 elevation, seen barely in advanced renal
failure, is a compensatory response to MMP-9 increase in
early CKD stages. Secondly, according to the hypothesis of
Newby (2008), the prevalence of MMP over TIMP activity
might result from the fact that in the early stages of
atherosclerosis, when monocytes migrate across the endo-
thelial monolayer, mainly MMPs are needed to facilitate the
penetration of cells. Subsequently, the TIMP overactivity
would be more evident when the in situ differentiation of
monocytes into macrophages takes place. The TIMP-2 high
concentrations, seen already in CKD stages 2–3, would
suggest the early response to the increase of MMP-2,
known for its proatherogenic activity. Thus, the progressive
elevation in CKD stages 4–5 would be a consequence of
further MMP-2 elevation.
However, the best way to evaluate the net effect of
balance between MMPs and their inhibitors was to assess
the values of MMP/TIMP ratios. Both MMP-9/TIMP-1 and
MMP-2/TIMP-2 ratio values in CKD patients differed
significantly from those in controls. In the case of the
MMP-9/TIMP-1 ratio, MMP-9 increased 2.4-fold in CKD
stage 2–3 patients vs. controls, whereas TIMP-1 did not,
causing the net 2.4-fold rise of the ratio value. When
children in CKD stages 2–3 and CKD stages 4–5 were
compared, both MMP-9 and TIMP-1 increased 1.8-fold, so
the ratio did not change. Taken together, the MMP-9
response dominated over that of TIMP-1 only in the early
CKD, and there was no difference between stages 2–3a n d4 –5.
When the MMP-2/TIMP-2 ratio was taken into account,
both MMP-2 and TIMP-2 concentrations were higher in
CKD stages 2–3 vs. controls. The elevation of protective
TIMP-2 was more pronounced (2.5-fold) than that of
proatherogenic MMP-2 (1.4-fold), thus causing the net
decrease of a ratio value. In CKD stages 4–5, when
compared to stages 2–3, the rise of both MMP-2 and
TIMP-2 was proportional and the ratio value, as in the case
of MMP-9/TIMP-1, did not change. Therefore, it seems that
disturbances in MMP/TIMP balance are already noticeable
in early CKD, whereas their correction and stabilization
take place in later stages of renal failure.
Conclusions
Our study describes for the first time the network of MMP/
TIMP systems in children with chronic kidney disease.
Relationships between these parameters, heat shock pro-
teins, and markers of endothelial dysfunction suggest the
possible role of MMPs and TIMPs in the stress response
and atherogenesis of CKD children. The progressive
changes in concentrations of MMPs and their inhibitors
may illustrate the adaptive response to unfavorable con-
ditions resulting from chronic dysfunction of the kidney.
However, the precise role of MMP/TIMP balance and its
relation to the stress response in the CKD pediatric
population need further investigation.
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